VLA-4 Integrin Can Mediate CD11/CD18-independent Transendothelial Migration of Human Monocytes

H. Eduardo Chuluyan and Andrew C. Issekutz
Departments of Pediatrics and Microbiology-Immunology, Dalhousie University, Halifax, Nova Scotia, Canada, B3J 3G9

Abstract

The migration of human monocytes across unactivated and activated human umbilical vein endothelium (HUVE) in response to chemotactic factors was studied, and the adhesion molecules involved were characterized. Migration of blood monocytes or U937 cell line–derived monocytes across unactivated HUVE induced by C5a, was partially inhibited (by 75%) by mAbs (R15.7 or 60.3) to CD18 of the CD11/CD18 complex on the monocyte. However, when the HUVE was pretreated for 5 h with IL-1α (0.1 ng/ml), TNF-α (100 U/ml), or LPS (1 ng/ml), migration induced by C5a was no longer inhibited; i.e., migration became CD18 independent. The monocyte CD18-independent migration was completely blocked by mAbs against α4 or β2, integrin chains of VLA-4. This migration was also partially inhibited by mAbs against vascular cell adhesion molecule-1 (VCAM-1), a major counter-receptor on HUVE for VLA-4, but not by mAbs to E-selectin or intercellular adhesion molecule-1. The significant CD18-independent migration across “unactivated” HUVE was also inhibited by mAbs against α4 or β1 chains of VLA-4, although mAbs against VCAM-1 did not inhibit under these conditions. Finally, considerable VLA-4-dependent transendothelial migration to C5a was also observed with monocytes from a patient with CD18 deficiency (leukocyte adhesion deficiency). These results suggest that (a) there is a major CD18-independent component in monocyte chemotactic factor-dependent migration across activated and unactivated endothelium; (b) that VLA-4 integrin on the monocyte has a major role in this migration; and (c) that VCAM-1 on activated endothelium functions as a counter-receptor in this process, but other ligands for VLA-4, especially on unactivated endothelium, may also be involved. (J. Clin. Invest. 1993. 92:2768–2777.) Key words: inflammation • chemotaxis • leukocyte • endothelium

Introduction

The movement of monocytes and polymorphonuclear leukocytes (PMNL)1 from blood into tissues is a characteristic fea-

1. Abbreviations used in this paper: HUVE, human umbilical vein endothelium; ICAM-1, intercellular adhesion molecule-1; LAD, leukocyte adhesion deficiency; PMNL, polymorphonuclear leukocytes; VCAM-1, vascular cell adhesion molecule-1; ZAP, zymosan-activated plasma.

Received for publication 26 April 1993 and in revised form 27 July 1993.

J. Clin. Invest. © The American Society for Clinical Investigation, Inc. 0021-9738/93/12/2768/10 $2.00
Volume 92, December 1993, 2768-2777
with PMNL (10, 28). However, in vivo studies clearly show that monocyte infiltration and migration occur rapidly at tissue sites injected with endothelium-activating cytokines such as IL-1, TNF-α, or LPS (29–31). One reason for such discrepancy could be that in vivo, both endothelial cell-dependent and monocyte chemotactic factor-dependent mechanisms may be simultaneously operative, since IL-1, TNF-α, and LPS are now known to induce the synthesis by connective tissue cells of chemotactic factors for leukocytes, including monocytes (32, 33). Furthermore, it is increasingly recognized that inflamed tissues and exudate fluids contain pathophysiologically relevant concentrations of monocyte chemotactic factors (e.g., C5a, leukotriene B4, and monocyte chemotactic protein-1 in conjunction with IL-1 and TNF (2, 32, 34, 35). In such tissues, the local vascular endothelium expresses leukocyte adhesion molecules, suggesting activation by the latter cytokines (29, 36, 37). Therefore, to model this complex in vivo situation, we investigated monocyte migration in vitro in response to chemotactic factors across both resting and IL-1, TNF-α, or LPS-activated HUVE. Under these migration conditions, we studied the monocyte and endothelium adhesion molecules required for monocyte migration. Our results indicate that chemotactic factors induce marked migration of monocytes across resting and activated endothelium. Furthermore, in the presence of an activated endothelium, the CD11/CD18 complex is not required for migration, but rather, the VLA-4 integrin can function as an alternative mechanism for the migration of monocytes.

Methods

Monoclonal antibodies. A number of function-blocking mAbs were generically provided for these studies. These included mAbs 60.3 (IgG2a from Dr. J. M. Harlan, University of Washington, Seattle, WA) (38), R15.7 (IgG1 from Dr. R. Rothlein, Boehringer Ingelheim, Ridgefield, CT) (39), and TS1/18 (IgG1 from Dr. T. A. Springer, Harvard University, Boston, MA) (40), which are known to block CD18 adhesion functions. Other mAbs reactive with monocytes were DREG200 (IgG1 from Dr. C. W. Smith, Baylor University, Dallas, TX), which blocks L-selectin (41), HP1/2 (IgG from Dr. R. Lobb, Biogen Inc., Cambridge, MA) against α4 (42) and Ab13 (IgG1 from Dr. K. Yamada, National Institute of Health, Bethesda, MD) against the β2 integrin chains (43). The mAb CSLEX against sialyl Lewis X blood group, W6/32 against HLA-Class I framework, 3C10 against CD14 and 543 against CR1 were all obtained from the American Type Culture Collection (Rockville, MD). The following mAbs reactive with HUVE were used: mAb 2G7 (IgG1, from Dr. W. Newman (Otsuka America Pharmaceuticals, Rockville, MD) and 4B9 (IgG3, from Dr. J. M. Harlan) both against VCAM-1 (16, 44), mAbs 5D10 (IgG2a as F(ab)2, from Dr. W. Newman) and 84H10 (IgG1; AMAC Inc., Westbrook, ME) both against human ICAM-1 (45) and mAb BB11 (IgG3 from Dr. R. Lobb) against E-selectin (46). These block adhesion function epitopes on their respective antigens. Purified IgG or F(ab)2 fragments were used as indicated at least twofold saturating concentrations as assessed by immunofluorescence or ELISA.

Reagents. Recombinant human IL-1α, which had a specific activity of 4 × 10^10 U/mg, was a gift from Dr. D. Urdal (Immunex Corp., Seattle, WA). Recombinant human TNF-α (specific activity = 5 × 10^10 U/mg) and IFN-α (10^10 U/mg) were gifts from Genentech Inc. (South San Francisco, CA). All of these cytokines contained ≤ 1 ng of LPS/μg. Each of the cytokines were diluted immediately before use in 0.1% LPS-free HSA (Connaught Laboratories, Don Mills, Ontario, Canada) in PBS. Escherichia coli 0111 LPS was from List Biologicals (Campbell, CA). Recombinant human C5a was a gift from CIBA-Geigy Pharmaceuticals (Summit, NJ).

Monocyte isolation from normal donors and a patient with CD18 deficiency: Sterile plasticware and pyrogen-free water (Travenol, Malton, Ontario, Canada) and solutions were used throughout. Venous blood from healthy human volunteers and from a patient with leukocyte adhesion deficiency (LAD) was collected into EDTA (0.1%) plus acid citrate dextrose (0.8 ml/10 ml of blood, acid citrate dextrose formula A; Travenol) anticoagulant. The LAD patient has previously been reported (47). He has severe CD18 deficiency with < 4% of normal expression of the CD11/CD18 molecular complex on leukocytes. The blood sample from this boy was collected by Dr. Zave Chad (Hôpital Ste. Justine, Montreal, PQ), along with a sample from a control, and couriered overnight to our laboratory for study. The red cells in the blood samples were separated by sedimentation with 6% dextran saline solution (Travenol) (1 part to 5 of blood) and the leukocyte-rich plasma was harvested. The leukocytes were sedimented (150 g × 10 min at 22°C), the pellet was resuspended in Ca2+-, Mg2+-free Tyrode’s solution with 5% autologous platelet-poor plasma, and labeled with 51Cr sodium chromate (25 μCi/ml) (Amersham Corp., Oakville, Ontario, Canada) by incubation for 30 min at 37°C. During this incubation, the osmolality of the medium was gradually increased in three steps from 290 to 360 mosmol by addition of 9% NaCl, as previously described by Boyum (48) and Recalde (49). This improved the monocyte purity and did not affect cell viability or function as reported previously (48, 49). After the incubation period, labeled leukocytes were washed once with Ca2+-, Mg2+-free Tyrode’s solution (360 mosmol), 5% PPP, and resuspended in hyperosmotic (360 mosmol) Ca2+-, Mg2+-free Tyrode’s solution containing 0.2% EDTA and 10% platelet-poor plasma—Percoll (Pharmacia Fine Chemicals, Dorval, PQ) to achieve 56% Percoll concentration (based on 100% = isotypic Percoll). Six different Percoll cushions of 2.5 ml each were layered in a 15-ml conical polypropylene tube with 73% Percoll at the bottom followed by 62%, 56% (containing the labeled leukocytes), 50%, 46%, and 40%. Density gradient centrifugation was at 400 g (25 min at 22°C) in a swinging bucket rotor. Six bands were resolved, harvested, and washed twice with isotonic Ca2+-, Mg2+-free Tyrode’s solution—0.1% HSA (LPS free). The purest monocyte fraction was recovered at the 46–40% Percoll interphase yielding 3 × 10^6 monocytes from 40 ml of starting blood with > 90% purity, > 95% viability by neutral red staining and trypan blue exclusion, and minimal platelet contamination. Platelets were found to band above the 40% Percoll cushion. Monocytes were identified by neutral red and nonspecific esterase staining (50), glass adherence and spreading and immunofluorescence staining of ≥ 90% of the cells, with mAbs 63D3 or 3C10 to CD14 and mAb OKM1 to Mac-1. The monocyte preparation contained < 3% contaminating CD2, CD3, or CD20 positive cells and there were no neutrophils, eosinophils, or basophils in the monocyte fraction. The monocytes were resuspended at a final concentration of 7 × 10^6/ml in RPMI 1640, 0.5% HSA containing 10 mM Hepes (pH 7.4) for migration studies.

Preparation of U937 cell line. The U937 cell line was obtained from the American Type Culture Collection and cultured (37°C–5% CO2) in suspension between 0.2 × 10^6 and 1 × 10^6 cells/ml in RPMI 1640 medium–10% FCS. Differentiation of these cells was induced by addition of dibutyryl camp (10−3 M) at a cell density of 0.3 × 10^6 cells/ml. Most studies were carried out on U937 cells after 48–72 h of exposure to dibutyryl cAMP, since expression of C5a receptors and the chemotactic response was fully developed at this time (51). The differentiated cells were 51Cr-labeled, washed, and resuspended at this time (1 × 10^6/ml) in RPMI 1640, 0.5% HSA, 10 mM Hepes for migration assays.

Endothelial cell cultures. Human umbilical vein endothelial cells were isolated and cultured in flasks as described by Jaffe et al. (52) and cultured on filters as previously described by us (22). Briefly, endothelial cells were isolated from umbilical cords after treatment with 0.5 mg/ml collagenase (Cooper Biomedical, Mississauga, Ontario, Canada), in 0.01 M PBS, pH 7.4, and grown in RPMI 1640 (ICN, Mississauga, Ontario, Canada) containing 2 mM L-glutamine, 2-mercaptoethanol, sodium pyruvate, penicillin G/streptomycin (Gibco Laboratories, Grand Island, NY) and supplemented with 20% FCS (Hyclone Laboratories, Logan, UT), 25 μg/ml endothelial cell growth supple-
dent (Collaborative Research, Lexington, MA), and heparin (45 μg/ml) (Sigma Chemical Co., St. Louis, MO). This is referred to as growth medium. Cells were cultured in gelatin-coated culture flasks (Nunc; Gibco Laboratories). The HUVE were detached using 0.025% trypsin/0.01% Versene (MA Bioproducts, Walkerville, MD) and cultured on PVP-free polycarbonate placed by HUVE before in 65-mm di culture plate inserts (Transwell 3415; Costar Corp., Cambridge, MA). The filters were first prepared by coating with 0.01% gelatin (37°C, 18 h) followed by application of 3 μg in 50 μl water of human fibronectin (Collaborative Research) at 37°C for 2 h. Fibronectin was then replaced by HUVE (2 × 10⁵ cells) from the first or second passage, added above the filter in 0.1 ml growth medium, and 0.6 ml growth medium was added to the lower compartment beneath the filter. The HUVE formed a tight permeability barrier in 5–6 d, and were evaluated for confluence before use by 125I-HSA diffusion as previously described (12).

Monocyte and U937 cell transendothelial migration. For migration assays, HUVE monolayers on the filters and the lower compartment beneath the filters were washed with RPMI 1640 and stimulated for 5 h by addition of IL-1α, TNF-α, or LPS to the lower compartment in fresh RPMI 1640 with 10% FCS. Before immersion of the HUVE filter unit, 0.1 ml of medium containing 7 × 10⁴ ⁵¹Cr monocytes or 10⁵ ⁵¹Cr U937 were added above the HUVE. After incubation (usually 90 min), migration was stopped by washing of the upper compartment twice with 0.1 ml RPMI 1640 to remove nonadherent monocytes or U937. The undersurface of the filter was then vigorously rinsed with 2 ml of ice-cold PBS/0.2% EDTA solution and collected into the lower compartment. The HUVE filter unit (upper compartment) was then placed into 0.7 ml of 0.5 M NaOH to allow dissolution of adhered monocytes. The cells that migrated into the lower compartment or were detached from the undersurface of the filters by the cold PBS/EDTA were lysed by addition of 0.5% Triton X-100. The NaOH solution bathing the filters (adherent cells) and the contents of the lower chamber (migrated cells) were analyzed for ⁵¹Cr and results are expressed as the percentage of the total ⁵¹Cr monocytes or U937 added above the HUVE, which were recovered in each fraction. All the stimulation conditions were performed with triplicate replicates.

Monoclonal antibody treatment. In some experiments, ⁵¹Cr-monocytes or ⁵¹Cr-U937 were treated for 20 min at room temperature with the mAbs indicated at saturating concentrations (20–40 μg/ml) as determined by immunofluorescence flow cytometry, and then tested for migration in the presence of the antibody. In some experiments, the HUVE was treated for 40 min at 37°C with saturating concentrations of mAbs as determined by ELISA, followed by the addition of the ⁵¹Cr labeled monocytes or U937 cells.

Statistical analysis. Student’s t test and ANOVA were used for statistical analysis of the data, with individual group means compared using post hoc Bonferroni analysis. P > 0.05 was not considered significant.

Results

Chemotactic factor–dependent monocyte migration. The optimal conditions for monocyte migration across HUVE monolayers was determined by performing dose response and time course experiments with the chemotactic factor, C5a. Fig. 1a shows that all C5a concentrations tested significantly increased monocyte migration above control levels with 5 × 10⁻¹⁰ M inducing the maximal monocyte response. The transendothelial migration of monocytes in response to C5a as a function of time is shown in Fig. 1b. Migration was detectable within 30 min and plateaued by 90–120 min. By this time, ~ 54% of the added monocytes placed in the upper chamber had traversed the endothelial monolayer and supporting filter. 90 min was the time chosen for the monocyte migration studies subsequently.

Endothelial cell dependent IL-1α–induced monocyte migration. In the case of PMNL, activation of the HUVE by IL-1 or TNF-α induces strong PMNL adhesion and marked transendothelial migration (25–35% of added PMNL) in this assay system as shown by us previously (12). As shown in Fig. 2a, IL-1α stimulation of the HUVE caused only a small amount (6.4%) of monocyte transendothelial migration but this was significantly greater than across unstimulated HUVE. This was associated with a more marked increase in monocyte adhesion (Fig. 2b). Neither an increase in the IL-1α concentration in the duration of stimulation with IL-1α ≤ 24 h or in the migration time enhanced the IL-1-induced monocyte migration (not shown). A small increase in monocyte migration and more marked adhesion was observed also when TNF-α or LPS were used to activate the HUVE as shown in Fig. 2. In contrast, IFN-γ stimulation of the HUVE had no effect on monocyte migration or adhesion.

Requirement for CD18 in chemotactic factor– and endothelium-dependent monocyte migration. We next examined the role of CD11/CD18 on monocytes in transendothelial migration. Fig. 3 shows that mAbs against the common CD18 β₂ integrin chain (60.3, R15.7, or TS1/18), but not control mAb (e.g., against CD14 [3C10] or CR1 [mAb543] [not shown])

![Figure 1](https://example.com/figure1.png)
Figure 2. Effect of IL-1α, LPS, TNF-α, and IFN-γ on monocyte migration (a) and adhesion (b) through endothelium. Human umbilical vein endothelial monolayers were grown on polycarbonate filters and were unstimulated or stimulated for 5 h with IL-1α (0.1 ng/ml), LPS (1 ng/ml), TNF-α (100 U/ml), or for <20 h with IFN-γ (200 U/ml). Medium was then exchanged and 51Cr-labeled monocytes were added above the monolayers and incubated for 90 min as described in Methods. Results are expressed as the percent of added monocytes that migrated through the HUVE filter unit (a) or remained adherent (b) to the HUVE. Values represent the mean±SEM of 16 separate experiments for IL-1α and three experiments with the other agents, performed in triplicate. *P < 0.05; ***P < 0.001; Student’s paired t test.

Figure 3. Effect of mAb against CD18 on C5a and IL-1α--induced monocyte transendothelial migration. HUVE monolayers were incubated with medium alone or IL-1α (0.1 ng/ml) for 5 h, after which time, medium was exchanged and 51Cr-monocytes were added. The monocytes were incubated with saturating amounts (20–40 μg/ml) of control mAbs (3C10 or 543) or mAbs to CD18 (i.e., R15.7, or 60.3 or TS1/18) (results were pooled) for 20 min at room temperature, and then added above the activated or unactivated HUVE. C5a (5 × 10⁻¹⁰ M) was added beneath the HUVE/filter unit. Data are expressed as in Fig. 1 and represent the mean±SEM of more than 16 experiments performed with triplicate wells. **P < 0.001 compared with control mAb-treated group + C5a, or C5a + IL-1α + anti-CD18--treated group, using post hoc Bonferroni analysis.

Figure 4. Effect of mAb against CD18 on C5a induced monocyte migration across TNF-α, LPS, or IFN-γ--activated endothelium. Labeled 51Cr-monocytes (7 × 10⁶) treated with control mAb 543 (anti-CR1) or 3C10 (anti-CD14) (open bars) or treated with mAb R15.7 against CD18 (hatched bars), were tested for C5a (5 × 10⁻¹⁰ M) induced transendothelial migration through unactivated HUVE or HUVE activated with TNF-α (100 U/ml, 5 h), LPS (1 ng/ml, 5 h) or IFN-γ (200 U/ml, 20 h). Data are expressed as the percent of added monocytes that migrated and represent the mean±SEM of three or more experiments performed in triplicate. **P < 0.001, ***P < 0.01 compared with C5a treated group, using post hoc Bonferroni analysis.
CD18 failed to inhibit the migration when the HUVE was previously activated by IL-1.

**Molecules involved in CD18-independent monocyte migration across IL-1α-activated endothelium.** We investigated the mechanisms that may contribute to CD18-independent migration by using mAbs directed against adhesion molecules on the surface of monocytes and on endothelial cells. The participation of E-selectin, ICAM-1, and VCAM-1 was assessed by incubating IL-1α-treated HUVE with specific blocking mAbs against E-selectin, ICAM-1, or VCAM-1, and quantitating the C5a-induced migration of monocytes, which were treated with mAb to CD18. All of the mAbs were present during the assay. Fig. 6a shows that mAb 2G7 (or 4B9, not shown) against VCAM-1 inhibited the CD18-induced migration induced by C5a across IL-1α-activated HUVE, suggesting that VCAM-1 on the HUVE is involved in CD18-independent migration. This inhibition by 2G7 was not potentiated by mAbs 5D10 or 84H10 (not shown) against ICAM-1 and BB11 against E-selectin in combination with 2G7. The control mAb W6/32 against an HLA-class I framework epitope had no effect on migration.

To determine the molecules involved on the surface of the monocyte in this CD18-independent migration, we preincubated the monocytes with mAb to CD18 plus blocking mAb HP1/2 to the α4 integrin chain of VLA-4 or mAb13 to β1 integrin, or mAb DREG200 to L-selectin or mAb CSLEX to the sialyl Lewis carbohydrate. Fig. 6b shows that of these, only the mAb against α4 (HP1/2) or against β1 integrin (mAb13) inhibited the CD18-independent migration. It is important to point out that the inhibition is almost complete by mAb HP1/2, as well as by mAb13, suggesting that VLA-4 on the monocyte is a major CD18-independent migration mechanism.

**Molecules involved in CD18-independent migration across unactivated endothelium.** The adhesion molecules involved in CD18-independent migration across unactivated HUVE were studied by using blocking mAbs against molecules on the surface of the monocyte and endothelial cell as above. As shown in Fig. 7a, the same mAbs used in Fig. 6 against E-selectin (BB11), ICAM-1 (5D10), or VCAM-1 (2G7) did not inhibit significantly the remaining C5a-induced migration of monocytes after treatment with mAb to CD18 (i.e., the CD18-independent component) across unactivated HUVE. This CD18-independent migration was ~ 30% of maximal as shown above in Fig. 3 (open bars). Even when these mAbs were used in combination, the migration on unactivated HUVE was not significantly inhibited.

The participation of VLA-4 in CD18-independent migration on unactivated HUVE was confirmed by preincubating the cells with the blocking mAb HP1/2, Ab13, DREG200, or CSLEX as also performed in Fig. 6. Fig. 7b shows that mAb against α4, i.e., HP1/2 or against β1 integrin (mAb13), inhibited the CD18-independent migration across unactivated HUVE, suggesting that VLA-4 is involved in CD18-independent migration across unactivated HUVE, as well as across IL-1α-activated HUVE (Fig. 6b).
Role of VLA-4 in C5a-induced monocyte migration across unactivated or IL-1α-activated HUVE. To more clearly determine the role of VLA-4 in C5a-induced monocyte migration through unactivated or IL-1α-activated HUVE, labeled ³¹Cr monocytes treated with mAb HP1/2 or α₅ chain of VLA-4 or mAb 60.3 to CD18 were tested for migration. Fig. 8a shows that HP1/2 alone caused a slight but not statistically significant decrease in C5a-induced migration across unactivated HUVE. The mAb against CD18 caused a 70% inhibition. Both mAbs together blocked migration almost completely (> 90% inhibition). However, when the HUVE was activated by IL-1α, neither mAb alone inhibited the C5a-induced migration. However, when used in combination, there was almost a total inhibition; i.e. near unstimulated migration in the absence of C5a.

Migration of CD11/CD18-deficient monocytes. We had the opportunity to perform one experiment with monocyttes from a patient reported previously (47) to have congenital LAD with nearly complete CD18 deficiency (< 4% of normal). Table I shows that the LAD patient’s monocytes were impaired in migration to C5a across unactivated HUVE, although they did show some response. However, migration to C5a increased markedly from 5.9% on unactivated HUVE to 19.5% when the HUVE was activated with IL-1α. Although this migration was less than the normal control used that same day, this could only be performed once because of the availability of patient blood. The migration of the LAD monocytes was completely blocked by mAb HP1/2 to α₅ and nearly completely by mAb13 to β₁ integrin, confirming that VLA-4 (α₅ β₁) is required for these CD11/CD18-deficient monocytes to migrate. The migration of the CD18-deficient monocytes was not inhibited by addition of mAb to CD18 (60.3) under any of the migration conditions tested (Table I).

**Table I. Migration of Leukocyte Adhesion (CD18) Deficiency Patients Monocytes through Endothelium**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Percent of monocytes migrated</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mAb</td>
</tr>
<tr>
<td>Unactivated</td>
<td>-</td>
</tr>
<tr>
<td>Unactivated</td>
<td>-</td>
</tr>
<tr>
<td>Unactivated</td>
<td>60.3</td>
</tr>
<tr>
<td>Unactivated</td>
<td>HP1/2</td>
</tr>
<tr>
<td>Unactivated</td>
<td>Ab13</td>
</tr>
<tr>
<td>IL-1α</td>
<td>-</td>
</tr>
<tr>
<td>IL-1α</td>
<td>-</td>
</tr>
<tr>
<td>IL-1α</td>
<td>60.3</td>
</tr>
<tr>
<td>IL-1α</td>
<td>HP1/2</td>
</tr>
<tr>
<td>IL-1α</td>
<td>Ab13</td>
</tr>
</tbody>
</table>

* HUVE were activated with IL-1α (0.1 ng/ml, 5 h) as indicated and monocytes were treated with mAb 60.3 (anti-CD18), HP1/2 (anti-α4 integrin) or Ab13 (anti-β1 integrin) for 20 min before addition for migration as in Fig. 6b. Migration was induced with C5a (5 x 10⁻⁹ M). ‡ Values are means of triplicate wells±SD.

**Figure 7.** Effect of mAbs against endothelial cell and monocyte adhesion molecules on monocyte CD18-independent migration through unactivated HUVE. (a) Unactivated HUVE was treated with saturating amounts of the designated mAbs for 40 min at 37°C as in Fig. 6a, after which labeled CD18 mAb (R15.7)-treated ³¹Cr monocytes (hatched bars) were added above the monolayer, and C5a was added to the lower compartment. (b) Labeled monocytes were incubated with mAbs to CD18 plus mAbs to sLex (CSLEX), L-selectin (DREG 200), α₅ (HP1/2), or β₁ (Ab13) integrins as in Fig. 6a at room temperature, and then added above HUVE. Data are expressed as the mean±SEM of four separate experiments, each performed with triplicate replicates. **P < 0.05 compared with (a) C5a- or (b) C5a + IL-1-treated group, using post hoc Bonferroni analysis.

**Figure 8.** The effect of antibody to VLA-4 on C5a-induced monocyte migration across unactivated or IL-1α-activated HUVE. Labeled monocytes were incubated with saturating amounts of mAb 60.3 to CD18 and/or HP1/2 to α₅ integrin of VLA-4 for 20 min at room temperature, and then added above unactivated HUVE (a), or HUVE activated with IL-1α (0.1 ng/ml, for 5h) (b). Migration was in response to C5a (5 x 10⁻⁹ M) added to the lower compartment. Data are expressed as the percent of added monocytes migrated and represent the mean±SEM of six separate experiments performed with triplicates. ***P < 0.001 compared with (a) C5a- or (b) C5a + IL-1-treated group, using post hoc Bonferroni analysis.
in vitro migration of monocytes and PMNLs and that PMNLs and monocytes of LAD patients, whose cells lack the CD11/CD18 complex, are defective in migration to chemotactic factors or across IL-1-activated endothelium (3, 6–9, 13). However, in these patients, monocytes, lymphocytes, and eosinophils have been observed in sites of inflammation and in delayed type hypersensitivity reactions (8, 9, 17), suggesting that other molecules in addition to CD11/CD18 may be involved in the transendothelial migration of these leukocytes. Our results confirm the existence of a major CD18-independent mechanism utilized by monocytes for transendothelial migration which, to our knowledge is demonstrated for the first time with an in vitro system. This mechanism requires VLA-4 on the monocyte and is most active when the endothelium is activated by IL-1, TNF-α, or LPS, and monocyte migration is potentiated by a chemotactic factor such as C5a or N-formyl peptides (see text).

Exposure of HUVE to IL-1 or TNF-α is known to induce PMNL adhesion and migration (3, 6, 12–14). These cytokines also increase monocyte adhesion and migration, although the migration response across activated HUVE is much weaker than with PMNL (21–24, 28). This monocyte behavior in vitro contrasts with in vivo findings, which show a strong monocyte recruitment to sites injected with these agents (3, 29–31). The weak in vitro monocyte migration across IL-1 or TNF-α-activated endothelium was considered by Hakker et al. (28) to be related to the type of subendothelial matrix used for the HUVE. However, even with attempts by these authors to optimize this component, monocyte migration across IL-1–treated HUVE was much less than for PMNL (28). In the system described here, we examined the effect of different types of matrix (data not shown), but observed no significant effect on the relatively low monocyte migration shown in Fig. 2, across IL-1–activated HUVE.

Another factor we considered to be contributing to the monocyte migration observed in vivo is the generation of chemotactic factors since in sites of inflammation (e.g., synovial fluid and lung), these direct monocyte acting factors and endothelial activating cytokines such as IL-1 and TNF-α can be present simultaneously (2, 3, 32–35). Furthermore, the vascular endothelium in inflamed tissues has been found to be “activated” with expression of leukocyte adhesion molecules (29, 37). Therefore, in this study, monocyte migration in response to chemotactic factors across unactivated and cytokine activated endothelium was investigated to simulate this in vivo situation. The migration induced by C5a was rapid and strong (Fig. 1), irrespective of whether or not the endothelium was activated (Figs. 3 and 8). This migration across unactivated HUVE was largely CD18 dependent, since three different mAbs against CD18-inhibited monocyte migration by 70–75% in response to C5a (Figs. 3 and 4) or FNLP (not shown). However, migration induced by these chemotactic factors across IL-1–, TNF-α–, or LPS-activated HUVE was completely CD18 independent because these same mAbs failed to inhibit migration at all under these conditions (Figs. 3 and 4 and text). The same results were obtained when the U937 cell line–derived monocyte-like cells were tested for migration under the same conditions (Fig. 5). This suggests that the CD18-independent migration observed is not the result of the purification process used to obtain blood monocytes, but rather, a property of monocyte lineage cells.

It is well known that on IL-1–, TNF-α–, or LPS-pretreated endothelium adhesion molecules such as E-selectin, ICAM-1, and VCAM-1 are upregulated, increasing the adhesiveness for PMNLs and monocytes (3, 17, 18). In this study, we show that the CD18-independent migration mechanism is enhanced by IL-1α, TNF-α, or LPS pretreatment of HUVE, but not by IFN-τ (Fig. 2). This is of interest because IFN-τ does not induce E-selectin or VCAM-1 on HUVE, although it does enhance expression of ICAM-1 (3, 16, 17, 21). This observation suggests ICAM-1 upregulation is not sufficient to mediate CD18-independent monocyte migration.

The role of E-selectin in monocyte and U937 cell binding has been previously studied. Although E-selectin appears to play a role in monocyte adhesion (21, 22, 24), it is not required in the CD18-independent migration observed here, since the adhesion blocking mAb BB11 against E-selectin (46) had no effect on migration alone (not shown) or in combination with mAbs against ICAM-1 (Fig. 6 a). Also L-selectin, which appears to be important for monocyte adhesion under shear force conditions (23), was not required for the migration we observed (Fig. 6 b). However, our results show that the treatment of the activated HUVE with mAbs 2G7 (or 4B9, not shown), which block VCAM-1–mediated adhesion to VLA-4 (16, 44), or the treatment of the monocytes with mAb HP1/2 to α4, which blocks the adhesion function of VLA-4 (42), essentially abolished the CD18-independent monocyte migration to C5a across IL-1–activated HUVE (Fig. 6 b). This finding, combined with the fact that mAb13, which reacts with β1 integrin chain and blocks adhesion functions of β1 integrins (43), was essentially as effective as inhibition for mAb HP1/2, strongly suggests that interaction between VCAM-1 on the HUVE and VLA-4 (αβ4) on the monocyte mediate CD18-independent migration across IL-1–activated HUVE. The importance of the α4 subunit, and specifically of the α4 cytoplasmic domain of VLA-4 for cell migration, has recently been elegantly shown using chimeric α4, α4, and α4 chains in transfected rhabdomyosarcoma cells (55). These findings are in agreement with our recent observations, that mAb to another β1 integrin α chain, namely to α5 (mAb 16) does not inhibit monocyte CD18-independent migration (data not shown).

It is important to point out that in the presence of mAb to CD18, mAbs HP1/2 and Ab13 were able to inhibit monocyte migration almost until basal levels across both unactivated and IL-1–activated HUVE, while mAbs 2G7 or 4B9 against VCAM-1 decreased only the IL-1–enhanced CD18-independent migration and the anti-VCAM-1 mAbs were less effective than the anti-α4 mAb (HP1/2) (Fig. 6, 7). These results do not appear to be caused by limiting amounts of mAbs because addition of four times higher concentrations of mAb to CD18 or to VCAM-1 gave the same results (data not shown). There may be several reasons for the more potent inhibition by mAb to α4 or β1 than by mAbs to VCAM-1: (a) VLA-4 can bind not only to VCAM-1, but also to CS-1 fragment of fibronectin, a ligand present also on unactivated HUVE and mAb HP 1/2 blocks VLA-4 binding to both (42, 56); (b) the mAbs used to block VCAM-1 on the activated HUVE bind to domain 1 on VCAM-1, while VLA-4 binds to more than one domain (57–59); and (c) another molecule present on activated and unactivated HUVE may also serve as a ligand for VLA-4. Currently, we are studying the second possibility by using mAbs against different domains of VCAM-1 (kindly provided by Dr. R.
Lobb). Preliminary results show that both domains 1 and 4 need to be blocked simultaneously to observe complete inhibition of CD18-independent monocyte migration. Thus, this suggests that VCAM-1 on the endothelium may be the only ligand for mediating the VLA-4-dependent migration observed here. Further studies are ongoing to confirm these results. The results with monocytes from a patient with LAD, congenitally deficient in CD11/CD18 (homozgyous) (< 4% of normal) (47) would appear to rule out the possibility that the mAbs to CD18 were not sufficient to block all CD11/CD18-dependent migration, since the LAD monocytes also migrated well across IL-1-activated HUVE, and to a lesser extent, across unactivated HUVE in response to C5a (Table I). These LAD monocytes also appeared to utilize VLA-4 as an alternative migration mechanism because mAb to $\alpha_\alpha$ or $\beta_2$-inhibited migration, while mAbs to CD18 had no effect on the migration of these monocytes (Table I).

On IL-1-activated HUVE, neither CD11/CD18 nor VLA-4 alone appear to be required for migration to chemotactic factors such as C5a because blocking either of these integrins alone did not inhibit the migration response (Fig. 8 b). Thus, one mechanism may substitute for the other on monocytes, and both mechanisms must be blocked to abolish monocyte migration across activated endothelium. In contrast, migration across unactivated endothelium in response to chemotactic factor is much more CD11/CD18 dependent (Fig. 8 a), and VLA-4 functions as a less efficient alternative mechanism, perhaps because unactivated endothelium expresses fewer or lower affinity ligands for VLA-4 on the monocytes.

In addition to monocytes, lymphocytes, eosinophils, and basophils express VLA-4 (56). Neutrophils lack this integrin. The VLA-4 on basophils, eosinophils, and T lymphocytes has been shown by a number of studies to contribute to the adhesion of these leukocytes to cytokine-activated endothelium (58, 60, 61). This adhesive function of VLA-4 involves, at least in part, VCAM-1 on the endothelium. However, most of the in vitro studies of the mechanism involved in the migration of T lymphocytes or eosinophils across IL-1-activated endothelium have identified a predominant role for CD11/CD18, with only a minor or insignificant contribution of VLA-4 or its ligand, VCAM-1, to the migration process (62, 63). This conclusion was also reached for T lymphocyte transendothelial migration in response to lymphocyte chemotactic factors (64). However, our finding that VLA-4 in monocytes can play a major role, in addition to CD11/CD18, in mediating cell migration is in agreement with a recent report that VLA-4 functions as a major mechanism by which eosinophils migrate across HUVE activated by IL-4 (but not IL-1) (65). In addition to these in vitro observations, there are now an increasing number of in vivo studies that implicate VLA-4 as an important integrin in T lymphocyte migration in the rat to dermal inflammatory reactions (e.g., delayed type hypersensitivity, TNF-α) (66), or to the central nervous system in experimental allergic encephalitis (67). In this species, monocyte infiltration into the lung in IgA immune complex arthritis (68) appears to also involve a VLA-4-mediated mechanism.

Thus, the in vitro observations reported here demonstrating a major role on monocytes for VLA-4, and of one of its major ligands, VCAM-1 in transendothelial migration, is in accord with the increasing evidence of an important role for VLA-4 in leukocyte migration in vivo. Further studies in vitro should allow analysis at the molecular level of the contribution to monocyte migration of ligands for VLA-4 in addition to VCAM-1, the role of VLA-4, CD11/CD18, and its subtypes (LFA-1, MAC-1, and gp150/95) in migration during various monocyte and endothelial cell activation conditions, and potentially lead to developing strategies for regulating monocyte migration in pathological conditions.

Acknowledgments

The authors are grateful for gifts of important reagents from Drs. R. Rothlein, J. M. Harlan, W. Newman, T. Springer, C. W. Smith, K. Yamada, R. Lobb, D. Urdal, and from Genentech Inc. and CIBA-Geigy Corp. We are also indebted to Dr. Z. Chad (Hôpital Ste. Justin, Montreal, PQ) for providing us blood from his patient with LAD disease and to Mrs. N. Lopes for her outstanding technical support throughout this study. The contribution of Dr. T. B. Issekutz to helpful discussions and assistance with flow cytometry analysis, and the excellent secretarial work of Ms. M. Hopkins and assistance with graphics by Mr. K. MacLeod are gratefully acknowledged.

This work was supported by an Izaak Walton Killam Children’s Hospital research project award to H. E. Chuluyan and by grant MA-7684 from the Medical Research Council of Canada held by A. C. Issekutz. H. E. Chuluyan was supported by an Izaak Walton Killam Children’s Hospital Research Fellowship and currently is the recipient of a Dalhousie Medical Research Fellowship.

References

12. Morzyczki, W., J. Sadowska, and A. C. Issekutz. 1990. Interleukin-1 and tumour necrosis factor α induced polymorphonuclear leukocyte-endothelial cell
ated human macrovascular endothelial cells. Immunology. 74:661-669.
thelial cell adhesion and neutrophil infiltration and leukocyte typing in rhe-
tant protein-1: structure and function. Cytokine. 4:131-152.
34. Firestein, G. S. 1992. Cytokines in autoimmune diseases. Concepts Im-
munopathol. 8:129-160.
spliced domain of vascular cell adhesion molecule 1 and an additional $\alpha_4$ integrin counter-receptor on stimulated endothelium. J. Exp. Med. 175:1433–1442.


